GlassScriptPhysician profile
Reuben H Stone
NPI 1326082231
$10,229.76
in general payments reported to CMS, 2019-2025
32 companies · $1,997 in 2025
The $1,997 reported for 2025 was more than what 83% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $943 · 2020: $908 · 2021: $1,847 · 2022: $1,652 · 2023: $1,415 · 2024: $1,469 · 2025: $1,997.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,861 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,860.51 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,039.67 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,777.71 | 2019-2025 | Jardiance |
| Abiomed | $1,154.07 | 2019-2025 | Impella |
| Amgen INC. | $913.29 | 2019-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $676.24 | 2021-2025 | Watchman Access System, Cds - Mct/Cem Monitoring |
| Astrazeneca Pharmaceuticals LP | $591.64 | 2020-2025 | Farxiga, Brilinta, Andexxa |
| Merck Sharp & Dohme LLC | $519.15 | 2021-2025 | Verquvo, Capvaxive |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $350.49 | 2019-2025 | Lifevest |
| Pfizer INC. | $278.57 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $273.05 | 2019-2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $206.71 | 2022-2025 | |
| Shockwave Medical, INC | $202.00 | 2022 | |
| Esperion Therapeutics, INC. | $188.67 | 2020-2024 | Nexletol |
| E.R. Squibb & Sons, L.L.C. | $137.96 | 2022-2025 | Camzyos, Eliquis |
| Medtronic, INC. | $124.66 | 2021-2025 | Symplicity G3 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Portola Pharmaceuticals, LLC | $122.32 | 2019 | |
| Chiesi USA, INC. | $94.06 | 2021 | |
| Novo Nordisk INC | $88.84 | 2023 | Ozempic |
| Scpharmaceuticals INC. | $78.48 | 2023-2024 | |
| Kestra Medical Technology Services, INC. | $63.64 | 2025 | Assure Wcd |
| Heartflow, INC. | $52.24 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $46.81 | 2019-2024 | Evkeeza |
| Ge Healthcare | $44.87 | 2025 | |
| Lexicon Pharmaceuticals, INC. | $41.59 | 2024 | |
| Inspire Medical Systems, INC. | $33.97 | 2024-2025 | Inspire |
| Silk Road Medical, INC. | $26.70 | 2022 | |
| Csl Behring | $22.44 | 2023 | Kcentra |
| Irhythm Technologies, INC. | $19.18 | 2023 | Zio Xt Patch |
| Daiichi Sankyo INC. | $18.59 | 2021 | |
| Glaxosmithkline, LLC. | $18.40 | 2025 | Shingrix |
| Actelion Pharmaceuticals US, INC. | $12.51 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $11.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reuben Stone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.